BioCryst Unveils ORLADEYO® (berotralstat) in Italy
Tuesday, February 20, 2024
BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) made an announcement today regarding the decision by the Italian Medicines Agency, Agenzia Italiana del Farmaco (AIFA), which has completed the reimbursement process and endorsed ORLADEYO® (berotralstat). This medication is recommended for the routine prevention of recurrent attacks of hereditary angioedema (HAE) in eligible patients aged 12 and above. This recommendation means that Italian HAE patients can now access the first oral, once-daily therapy for preventing recurring HAE attacks.
Charlie Gayer, the chief commercial officer at BioCryst, expressed enthusiasm about the AIFA recommendation, stating that it expands access to modern prophylaxis in Italy and is great news for Italian clinicians and HAE patients.
This decision from AIFA follows the European Commission (EC) granting marketing authorization for ORLADEYO in April 2021.
BioCryst Pharmaceuticals is a global biotechnology company dedicated to improving the lives of individuals affected by complement-mediated and other rare diseases. Through expertise in structure-guided drug design, BioCryst develops first-in-class or best-in-class oral small-molecule and protein therapeutics to address challenging-to-treat diseases. The company has successfully commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies.
Source: globenewswire.com
